On March 5, 2017 MonTa Biosciences reported that attends BioEurope Spring in Barcelona to have meetings with more than 10 of the top 20 pharma companies (Press release, MonTa Biosciences, MAR 5, 2017, View Source [SID1234618636]). The major aim is to get feedback on our technology and learn more about interests from big pharma and explore potentials for future partnership.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

(Filing, Annual, Sanofi, 2016, MAR 3, 2017, View Source [SID1234517980])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On March 3, 2017 Atreca, Inc., a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, reported that Tito Serafini, Ph.D., President, Chief Executive Officer, and Co-­Founder, will present at the Cowen and Company 37th Annual Health Care Conference on Wednesday, March 8, 2017 at 2:00 p.m. Eastern Time at the Boston Marriott Copley Place (Press release, Atreca, MAR 3, 2017, View Source [SID1234522954]). Dr. Serafini will provide an overview of Atreca’s technologies, programs and progress.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

(Filing, Annual, QIAGEN, 2016, MAR 3, 2017, View Source [SID1234518018])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On March 2, 2017 Geron Corporation (Nasdaq:GERN) reported an abstract submitted by Janssen Research & Development, LLC describing non-clinical data on imetelstat has been accepted for presentation as a poster at the 2017 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting to be held in Washington, D.C. from April 1-5, 2017 (Press release, Geron, MAR 2, 2017, View Source;p=RssLanding&cat=news&id=2250980 [SID1234517934]). The abstract is available on the AACR (Free AACR Whitepaper) website at www.aacr.org.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Abstract Title: Telomerase inhibitor imetelstat in combination with the BCL-2 inhibitor venetoclax enhances apoptosis in vitro and increases survival in vivo in acute myeloid leukemia (Abstract #1101)

AACR Session Title: Combination Therapy 1
Session Date: Monday, April 3, 2017
Session Time: 8:00 a.m. ET – 12:00 p.m. ET
In accordance with AACR (Free AACR Whitepaper) policies, abstracts submitted to the AACR (Free AACR Whitepaper) Annual Meeting are embargoed from the time of submission. To be eligible for presentation at the AACR (Free AACR Whitepaper) Annual Meeting, information contained in the abstract, as well as additional data and information to be presented at the Annual Meeting, may not be made public before the abstract has been presented in connection with the AACR (Free AACR Whitepaper) Annual Meeting.